Evaluation of a human mucosal tissue explant model for SARS-CoV-2 replication

• Published in: PloS one 2023-09, Vol.18 (9), p.e0291146-e0291146
• Main Authors: Gordhan, Bhavna Gowan, Herrera, Carolina, Pillay, Azure-Dee, Seiphetlo, Thabiso, Ealand, Christopher Shawn, Machowski, Edith, Singh, Natasha, Seatholo, Ntombexolo, Otwombe, Kennedy, Lebina, Limakatso, Frise, Rebecca, Scarlatti, Gabriella, Chiodi, Francesca, Martinson, Neil, Fox, Julie, Kana, Bavesh Davandra
• Format: Article
• Language: English
• Subjects: Analysis; Antibodies; Biology and life sciences; COVID-19; COVID-19 vaccines; Disease transmission; Explants; Health aspects; Host-pathogen interactions; Infection; Infections; Infectivity; Laboratories; Laboratory models; Medical research; Medicin och hälsovetenskap; Medicine and health sciences; Medicine, Experimental; Mucosa; Pandemics; Pathogenesis; Pathogens; Prevention; Replication; Research and analysis methods; Severe acute respiratory syndrome coronavirus 2; Strains (organisms); Tissues; Vaccination; Viral diseases; Viruses
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0291146

With the onset of COVID-19, the development of ex vivo laboratory models became an urgent priority to study host-pathogen interactions in response to the pandemic. In this study, we aimed to establish an ex vivo mucosal tissue explant challenge model for studying SARS-CoV-2 infection and replication. Nasal or oral tissue samples were collected from eligible participants and explants generated from the tissue were infected with various SARS-CoV-2 strains, including IC19 (lineage B.1.13), Beta (lineage B.1.351) and Delta (lineage B.1.617.2). A qRT-PCR assay used to measure viral replication in the tissue explants over a 15-day period, demonstrated no replication for any viral strains tested. Based on this, the ex vivo challenge protocol was modified by reducing the viral infection time and duration of sampling. Despite these changes, viral infectivity of the nasal and oral mucosa was not improved. Since 67% of the enrolled participants were already vaccinated against SARS-CoV-2, it is possible that neutralizing antibodies in explant tissue may have prevented the establishment of infection. However, we were unable to optimize plaque assays aimed at titrating the virus in supernatants from both infected and uninfected tissue, due to limited volume of culture supernatant available at the various collection time points. Currently, the reasons for the inability of these mucosal tissue samples to support replication of SARS-CoV-2 ex vivo remains unclear and requires further investigation.